IPP Bureau
Vaishali Pharma signs partnership agreement with Jark Pharma
By IPP Bureau - December 22, 2022
As per the agreement, NSE-listed Vaishali Pharma Limited will take over the entire domestic and international marketing of Jark Pharma’s portfolio of quality based ayurvedic products
Lynparza in combination with Abiraterone and Prednisone approved in the EU as treatment for metastatic castration-resistant prostate cancer
By IPP Bureau - December 22, 2022
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
Supriya Lifescience signs solar agreement with Enrich Energy
By IPP Bureau - December 22, 2022
The project will generate and supply green energy to fulfill about 50% present consumption of the company
Torrent board approves Scheme of Amalgamation of Curatio Health Care
By IPP Bureau - December 22, 2022
The scheme is subject to statutory and regulatory approvals as may be necessary.
BeatO appoints Dr. Navneet Agrawal as Chief Clinical Officer
By IPP Bureau - December 22, 2022
He has published more than 100 research papers in several prestigious national and international journals
WBF signs MOU with Sharda University to help advance biocontrol sector
By IPP Bureau - December 21, 2022
Indira IVF forays into diagnostic business with ‘Indira Pathlabs’
By IPP Bureau - December 21, 2022
Indira IVF integrates diagnostics services with a special focus on women & child care to increase accessibility for patients
Cadila Pharmaceuticals appoints Ashraf Allam as Global COO
By IPP Bureau - December 20, 2022
Allam was serving recently as the CEO at Public Investment Fund
Ipca acquires further 6.53% of equity share of Trophic Wellness
By IPP Bureau - December 20, 2022
Ipca Laboratories now holds 58.88% of the paid-up equity share capital of the company.
Emcure conducts oral and health check-up camps for students in Pune
By IPP Bureau - December 20, 2022
The camps were organised along with the doctors from Bharti Vidyapeeth Dental College and Hospital, Katraj, Pune, and Emcure’s occupational health centre (OHC) doctors
Glenmark Pharmaceuticals receives ANDA approval for Nicardipine Hydrochloride Capsules
By IPP Bureau - December 20, 2022
According to IQVIA sales data for the 12-month period ending October 2022, the Cardene Capsules, 20 mg and 30 mg market achieved annual sales of approximately US $10.9 million
USFDA inspection at Alembic Pharmaceuticals’ facility at Jarod
By IPP Bureau - December 20, 2022
None of the observations are related to data integrity and management believes that they are addressable
Enhertu to demonstrate a significant survival benefit vs. chemotherapy
By IPP Bureau - December 20, 2022
Diabetic neuropathic pain field presents significant opportunity for drug developers, says GlobalData
By IPP Bureau - December 20, 2022
36.4% of patients with diabetic neuropathic pain in 2021 were completely treatment refractory and would benefit from new treatment options.
